1. Home
  2. AMR vs MESO Comparison

AMR vs MESO Comparison

Compare AMR & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Metallurgical Resources Inc.

AMR

Alpha Metallurgical Resources Inc.

HOLD

Current Price

$187.20

Market Cap

2.7B

Sector

Energy

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.59

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMR
MESO
Founded
2016
2004
Country
United States
Australia
Employees
N/A
81
Industry
Coal Mining
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.2B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
AMR
MESO
Price
$187.20
$14.59
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$181.50
N/A
AVG Volume (30 Days)
244.2K
261.0K
Earning Date
05-08-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,129,481,000.00
N/A
Revenue This Year
$13.55
$644.56
Revenue Next Year
$13.69
$38.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$102.13
$9.88
52 Week High
$253.82
$21.50

Technical Indicators

Market Signals
Indicator
AMR
MESO
Relative Strength Index (RSI) 43.35 47.07
Support Level $151.08 $14.44
Resistance Level $187.87 $16.77
Average True Range (ATR) 11.63 0.59
MACD -2.74 0.07
Stochastic Oscillator 11.05 41.25

Price Performance

Historical Comparison
AMR
MESO

About AMR Alpha Metallurgical Resources Inc.

Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: